Role of leutenising hormone LH and insulin resistance in polycystic ovarian syndrome
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20174029Keywords:
Insulin resistance, Luteinizing hormone, Polycystic ovarian syndromeAbstract
Background: Polycystic ovary syndrome (PCOS) is the most frequent endocrine disorder seen in pre-menopausal women, affecting 5-10% of this population. It is characterized by menstrual irregularities and clinical hyperandrogenism such as hirsutism, seborrhoea and acne. PCOS women have insulin resistance, which results in compensatory hyperinsulinemia. A number of findings suggest that hyperinsulinemia may play a central role in the development of hyperandrogenism. This study is under taken to measure insulin resistance and leutenising hormone (LH) in PCOS patients and to see the relationship of insulin resistance with leutenising hormone (LH).
Methods: Case control study was done taking 60 women PCOS and 60 age matched healthy women as controls. In all the subjects, concentrations of fasting plasma glucose estimated using enzymatic methods in semiautoanalyser. Fasting serum insulin and leutenising hormone (LH) measured by CLIA using Lumax-CLIA microplate reader. HOMA IR was calculated from estimated parameters.
Results: The concentration of fasting serum insulin,fasting plasma glucose,HOMA –IR and leutenising hormone(LH) in controls are 9.33±3.08 µIU/ml,94.38±10.36mg/dl,12.16±0.67and 4.67±1.94 mIU/ml respectively; in PCOS cases they are 24.50±10.03µIU/ml,114.20±30.38 mg/dl,7.29±4.08 and 15.75±7.51 mIU/ml respectively. The mean concentrations of all the parameters were significantly (p value<0.05) increased in women with polycystic ovarian syndrome when compared with healthy women.
Conclusions: This study shows that 75% of pcos women were insulin resistant and HOMA IR shows a positive correlation (r value 0.48, p<0.05) with serum leutenising hormone(LH).
References
Wilson EE. Polycystic ovarian syndrome and Hyperandrogenism. In: Schorge JO, Schaffer JI, Hairorson LM, Hoffman BL, Bradshaw KD and Cunningham FG. Williams Gynecoloy. New York: MC Graw Hill. 2008;383-99.
Norman R, Hickey T, Moran L. Boyle J, Wang J, Davies M. Polycystic ovarian syndrome, diagnosis and etiology, International congress series. 2004;126:247-63,
Solomon CG. The epideomology of PCOS. Prevalance and associated disease risk. Endocrine Metab Clin North Am. 1999;28(2):247-63.
Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. TheInsulin‐Related Ovarian Regulatory System in Health and Disease. Endocr Rev. 1999;20:535‐82.
Ioan C, Costin N, Mihu D. Lipid parameters in patients with polycystic ovary syndrome. Applied Medical Informatics. 2012;31:27-32.
Kalra P, Bansal B, Nag P, Singh JK, Gupta RK, Kumar S, et al. Abdominal fat distribution and insulin resistance in Indian women with polycystic ovarian syndrome. Fertility and Sterility. 2009; 91:1437-40.
Otto-Buczkowska E, Jarosz-Chobot P, Deja G. Early metabolic abnormalities-insulin resistance, hyperinsulinemia, impaired glucose tolerance and diabetes, in adolescent girls with polycystic ovarian syndrome. Przegl Lek. 2006;63(4):234-8.
Melmed S, Anterior pituitary. In Kronenberg H, Melmed S, Polonsky K,Larsen P et al editors. Williums textbook of endocrinology.11th ed. Canada: Saunders Elsevier; 2008:155-262.
Krishna M and Laloraya M. Insulin paradox pcos implication on mechanism and pathogenesis. Health Science. 2013:2(1):jsoo4D.
Desai V, Prasad N, Manohar S, Sachan A. Oxidative Stress in Non-Obese Women with Polycystic Ovarian Syndrome. J Clin Diagn Res. 2014;8(7): CC01-3.
Yilmaz M, Bukan N, Ersoy R. Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome. Human Reproduction. 2005;20(9):2414-20.
Kalra A, Nair S, Rai L. Association of obesity and insulin resistance with dyslipidemia in Indian women with polycystic ovarian syndrome. Indian J Med Sci. 2006;60(11):447-53.
Saxena P, Prakash A, Nigam A. Efficacy of 2-hour post glucose insulin levels in predicting insulin resistance in polycystic ovarian syndrome with infertility. J Hum Reprod Sci. 2011;4(1)20-2.
Venkatesan AM, Dunaif A, Corbould A. Insulin resistance in polycystic ovary syndrome: progress and paradox. Recent Prog Horm Res. 2001;56:295-308.
Corbould A, Zhao H, Mirzoeva S, Aird F, Dunaif A. Enhanced Mitogenic Signaling in Skeletal Muscle of Women With Polycystic Ovary Syndrome. Diabetes. 2006;55(3):751-9.
Mutib MT, Hamdan FB, Alsalihi AR. Anthropometric, hormonal and biochemical indices in patients with polycystic ovarian syndrome. Iraqi J Embryos and infertility researches. 2013;3(6).
Feuser C, Barbosa J, Dasilva E. Current insight into gonadotropic pituitary function in the polycystic ovary syndrome. Asian Pacific J Reproduct. 2014;3(1):64-70.
Fulghesu AM, Cucinelli F, Pavone V. Changes in luteinizing hormone and insulin secretion in polycystic ovarian syndrome. Human reproduction. 1999;14(3):611-7.
Cheung L, Ma R, Lam P. Cardiovascular risks and metabolic syndrome in hong kong Chinese women with polycystic ovary syndrome. Human Reproduction. 2008;23(6):1431-8.
Liu N, Ma Y, Wang S. Association of the genetic variants of luteinizing hormone, luteinizing hormone receptor and polycystic ovarian syndrome. Reproduct Biol Endocrinol. 2012;10(1):36.
Baillargeon J, Nestler J. Polycystic Ovary Syndrome: A Syndrome of Ovarian Hypersensitivity to Insulin? J Clin Endocrinol Metab. 2006;91(1):22-4.
